Lumida
/KROS
⌘K
Keros Therapeutics Inc

Keros Therapeutics Inc

KROS
$10.64USD+0.28%+0.03 today

MARKET CAP

210.6M

P/E (TTM)

FWD P/E

DAY RANGE

$10 – $11

52W RANGE

$10
$23

AI Summary

Stalk
StalkMedium

The recent momentum breakout above the consolidation cluster on rising volume confirms demand absorption and supports a bullish medium-term bias in early Stage 1 repair. However, price is currently extended above the rising 9/21 EMAs with no pullback, offering limited execution edge. We defer engagement and await a pullback into the dynamic support zone around the 9 and 21 EMAs for optimal entry.

  • Added to Russell Microcap and 2000 Value-Defensive indices, enhancing liquidity.
  • Analysts rate Buy, average target $21.83 (+98.6% vs. $10.86 current).
  • Q1 loss of $1.21/sh missed forecasts by ~16%, underscoring cash burn.
Full analysis →
Insider Trades8 trades
DateSideTickerInsiderRoleSharesPriceMkt Cap52W High52W LowValue% ChgRuleAI View
Apr 2, 2026BuyKROSJasbir SeehraCHIEF EXECUTIVE OFFICER55,000$0.30$210.6M-52.82%+9.80%$16.5K+9.43%Stalk
Feb 19, 2026SellKROSJasbir SeehraCHIEF EXECUTIVE OFFICER7,015$16.17$210.6M-52.82%+9.80%$113.4K-1.79%Stalk
Feb 18, 2026SellKROSLorena Raquel LernerChief Science Officer3,873$16.35$210.6M-52.82%+9.80%$63.3K-11.07%Stalk
Feb 18, 2026SellKROSKeith RegnanteCHIEF FINANCIAL OFFICER4,739$16.35$210.6M-52.82%+9.80%$77.5K-10.77%Stalk
Feb 18, 2026SellKROSEsther ChoSVP, General Counsel4,745$16.35$210.6M-52.82%+9.80%$77.6K-10.66%Stalk
Apr 4, 2025BuyKROSJasbir SeehraCHIEF EXECUTIVE OFFICER49,367$0.30$210.6M-52.82%+9.80%$14.8K+9.77%Stalk
Jan 4, 2024SellKROSKeith RegnanteCHIEF FINANCIAL OFFICER80,000$30.64$210.6M-52.82%+9.80%$2.5M+0.00%10b5-1Stalk
Nov 4, 2023SellKROSKeith RegnanteChief Financial Officer80,000$30.64$210.6M-52.82%+9.80%$2.5M+0.00%10b5-1Stalk